Spruce Biosciences confirms positive FDA pre-BLA meetings for ta-ert
Spruce Biosciences says its pre-BLA meetings with the FDA for ta-ert were positive and that its BLA submission remains on track for Q4 2026.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.